Cipriano Massimiliano, Ruberti Enzo, Giacalone Andrea
Department of Laparoscopic Surgery, Umberto I General Hospital, Medical School Sapienza University, Rome, ITA.
Neurology, Sapienza University, Rome, ITA.
Cureus. 2020 Mar 26;12(3):e7422. doi: 10.7759/cureus.7422.
It's not news to tell you that the coronavirus, known as COVID-19, is a worldwide pandemic. The initial outbreak of this novel virus in Wuhan in the Hubei province of China, first described in December 2019, has since moved on to being declared a pandemic by the World Health Organization. The classic description of COVID-19 is a respiratory illness that manifests with fever, dry cough, and dyspnea on exertion. However, gastrointestinal (GI) complication of COVID-19 is emerging as well. This was observed with similar viral respiratory illnesses, such as severe acute respiratory syndrome (SARS), which emerged in 2003, and the Middle East respiratory syndrome (MERS), which emerged in 2012. In a recently published, single-center case series of 138 consecutive hospitalized patients with confirmed COVID-19, investigators reported that approximately 10% of patients initially presented with GI symptoms, prior to the subsequent development of respiratory symptoms. Common and often very subtle symptoms included diarrhea, nausea, and abdominal pain, with a less common symptom being nonspecific GI illness. New studies are expanding our understanding of the possible fecal transmission of COVID-19. Assessment by polymerase chain reaction (PCR) has provided evidence of the virus in the stool and the oropharynx outside the nasopharynx and respiratory tract. Virus in the stool may be evident on presentation and last throughout the course of illness resolution for up to 12 days after the respiratory virus evidence is gone. In fact, in one of the most recent studies looking at 73 patients, approximately 24% remained positive in their stool for evidence of the virus, though not necessarily infection, after showing negative in respiratory samples. The Centers for Disease Control and Prevention (CDC) recommends that after two negative respiratory tests separated by ≥ 24 hours, patients can be dismissed from having transmissibility infection risk for COVID-19. The potential for fecal-oral transmission of COVID-19 needs to be strongly considered. Considering these cases and the lessons from SARS, many authors recommend that real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from feces should be performed routinely in SARS-CoV-2 patients.
告诉你新型冠状病毒(COVID-19)已成为全球大流行疾病,这已不是什么新闻了。这种新型病毒于2019年12月首次在中国湖北省武汉市被发现,随后世界卫生组织宣布其为大流行病。COVID-19的典型症状是呼吸系统疾病,表现为发热、干咳和活动时呼吸困难。然而,COVID-19的胃肠道并发症也逐渐显现。2003年出现的严重急性呼吸综合征(SARS)和2012年出现的中东呼吸综合征(MERS)等类似的病毒性呼吸道疾病也有这种情况。在最近发表的一项单中心病例系列研究中,对138例连续住院的确诊COVID-19患者进行观察,研究人员报告称,约10%的患者在随后出现呼吸道症状之前,最初表现为胃肠道症状。常见且往往非常轻微的症状包括腹泻、恶心和腹痛,不太常见的症状是不明原因的胃肠道疾病。新的研究正在扩展我们对COVID-19可能通过粪便传播的理解。聚合酶链反应(PCR)评估已证实病毒存在于粪便以及鼻咽和呼吸道之外的口咽部。粪便中的病毒在疾病表现时可能就很明显,并且在呼吸道病毒检测呈阴性后的疾病恢复过程中可能持续长达十二天。事实上,在最近一项针对73名患者的研究中,约24%的患者呼吸道样本检测呈阴性后,粪便中仍有病毒存在迹象,但不一定是感染。美国疾病控制与预防中心(CDC)建议,在两次间隔≥24小时的呼吸道检测均为阴性后,患者可被判定不再具有COVID-19传播性感染风险。需要高度重视COVID-19通过粪口传播的可能性。考虑到这些病例以及从SARS中吸取的教训,许多作者建议应对COVID-19患者常规进行粪便中严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的实时逆转录-聚合酶链反应(rRT-PCR)检测。